Ex-Acrobot CEO to head up Reapplix
This article was originally published in Clinica
Executive Summary
Privately-held Danish wound care specialist Reapplix has appointed Graeme Brookes CEO. Mr Brookes previously led robotic technology specialist Acrobot, before it was acquired by UK orthopedics firm Stanmore Implants in 2010. After the takeover, he was Stanmore’s global vice-president for product development and product marketing. Mr Brookes has also held senior roles at Johnson & Johnson and Advanced Medical Solutions. He replaces Reapplix founder Niels Erik Holm, who will become chief operating officer. Birkerød-based Reapplix’s lead product is LeucoPatch, a proprietary biological “patch” that is produced at point of use from a patient’s own blood, and is designed for the management of hard to heal wounds. The patch, which is already CE marked for sale in Europe, is currently being evaluated for the treatment of diabetic foot ulcers in a randomized controlled clinical study. Reapplix is backed by three leading Danish investors, Novo Seeds, SEED Capital and Vækstfonden (The Danish Growth Fund).
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.